Clinical Trial Update: Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing gefitinib to vinorelbine/platinum as adjuvant therapy in Stage II-IIIA(N1-N2) non-small cell lung cancer with EGFR mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• Vinorelbine/Platinum (vinorelbine/platinum)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN